Corticosteroid Usage and Dosage Guidelines

Indications and Dosage

For allergic rhinitis, the American Academy of Otolaryngology-Head and Neck Surgery recommends intranasal formulation dosages of 1 spray per nostril daily for ages 2-5 years, 2 sprays per nostril daily for ages 6-11 years, and 2 sprays per nostril 1-2 times daily for ages ≥12 years 1, 2
For lichen sclerosus with topical steroid-resistant areas, the British Association of Dermatologists suggests intralesional triamcinolone 10-20 mg after excluding malignancy 3
For alopecia areata, the British Association of Dermatologists recommends intralesional injection of triamcinolone acetonide 5-10 mg/mL into affected areas 4
For atopic dermatitis, the American Academy of Dermatology advises against chronic use due to risk of rebound flares, and recommends a dosage range of 0.5-1.0 mg/kg with a tapering schedule to prevent adrenal suppression if used as transitional therapy in severe cases 5

The American Academy of Otolaryngology-Head and Neck Surgery and the American Academy of Dermatology warn against prolonged use due to potential side effects, including skin atrophy and telangiectasia, hypothalamic-pituitary-adrenal axis suppression, growth suppression in children, hypertension, glucose intolerance, and decreased bone density 1, 2, 5, 6
The American Academy of Dermatology recommends monitoring blood pressure, considering ophthalmologic examination, evaluating for hypothalamic-pituitary-adrenal axis suppression, and tracking growth velocity in children for long-term administration 1, 2, 5, 6

The American Academy of Otolaryngology-Head and Neck Surgery advises against use in patients with a history of hypersensitivity to triamcinolone acetonide or any components of the formulation, and recommends caution in patients with HIV who may absorb steroids at a higher rate 1, 2

Corticosteroid‑containing weight‑loss medications are contraindicated for women who are pregnant or actively trying to conceive. This recommendation is based on safety concerns for fetal development and is supported by evidence published in Diabetes Care (2022) 7.
Women of reproductive potential should receive counseling on reliable contraception methods before initiating corticosteroid‑containing weight‑loss therapy. The same guideline emphasizes the importance of preventing unintended pregnancy while on these agents 7.